Safety of Lenalidomide 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients with Lower-Risk MDS
At ASH 2015, Dr. Antonio Almeida from Instituto Portugues de Oncologia de Lisboa discussed his poster titled "Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)."
Recent Video
Most Popular
Specialties :                    Search :


MPNUniversity.tv is a member of the Oncology.TV family of oncology medical education websites. MPNUniversity.tv offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).